Immunogen, Inc. (IMGN) Misses Q4 EPS by 51c

Immunogen, Inc. (NASDAQ: IMGN) reported Q4 EPS of ($0.83), $0.51 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $5.74 million versus the consensus estimate of $9.72 million.

For earnings history and earnings-related data on Immunogen, Inc. (IMGN) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Cantor Fitzgerald Reiterates Overweight Rating on Global Net Lease (GNL)